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Abstract
Background: Although benzodiazepines are effective, long-term use is not recommended because of potential
adverse effects; the risks of tolerance and dependence; and an increased risk of hip fractures, motor vehicle
accidents, and memory impairment. The estimated prevalence of long-term benzodiazepine use in the general
population is about 2,2 to 2,6%, is higher in women and increases steadily with age. Interventions performed by
General Practitioners may help patients to discontinue long-term benzodiazepine use. We have designed a trial to
evaluate the effectiveness and safety of two brief general practitioner-provided interventions, based on gradual
dose reduction, and will compare the effectiveness of these interventions with that of routine clinical practice.
Methods/Design: In a three-arm cluster randomized controlled trial, general practitioners will be randomly
allocated to: a) a group in which the first patient visit will feature a structured interview, followed by visits every 2-
3 weeks to the end of dose reduction; b) a group in which the first patient visit will feature a structured interview
plus delivery of written instructions to self-reduce benzodiazepine dose, or c) routine care. Using a computerized
pharmaceutical prescription database, 495 patients, aged 18-80 years, taking benzodiazepine for at least 6 months,
will be recruited in primary care health districts of three regions of Spain (the Balearic Islands, Catalonia, and
Valencia). The primary outcome will be benzodiazepine use at 12 months. The secondary outcomes will include
measurements of anxiety and depression symptoms, benzodiazepine dependence, quality of sleep, and alcohol
consumption.
Discussion: Although some interventions have been shown to be effective in reducing benzodiazepine
consumption by long-term users, the clinical relevance of such interventions is limited by their complexity. This
randomized trial will compare the effectiveness and safety of two complex stepped care interventions with that of
routine care in a study with sufficient statistical power to detect clinically relevant differences.
Trial Registration: Current Controlled Trials: ISRCTN13024375
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Benzodiazepines (BZDs) are used to treat anxiety disor-
ders and sleep disturbance; as adjuvant therapy in
patients with schizophrenia, depression, and alcohol
withdrawal problems; and as muscle relaxants. BZDs are
widely prescribed throughout Spain and in most Wes-
tern countries [1-3]. The last Spanish National Health
Survey [4] showed that 14.3% of subjects had used BZD
in the previous 2 weeks, including 29.9% of women over
65 years of age. In 2006, the consumption of defined
daily doses (DDDs) per 1,000 inhabitants per day (DHD)
in Spain was 69.9 [5], and significant variability among
regions of the country was evident [5,6].
Although BZDs are effective in the short term, long-
term use is usually not recommended because of poten-
tial adverse effects and the risks of development of toler-
ance and dependence. Prolonged use of BZDs may
produce somnolence, memory impairment, and daytime
drowsiness; may cause falls resulting in hip fractures;
and may result in motor vehicle accidents [7-9]. A
meta-analysis evaluating the risks and benefits of long-
term BZD use to treat insomnia in adults aged > 60
years concluded that, although sleep quality improved,
the magnitude of the effect was small and drug use
exposed patients to an increased risk of adverse effects
[10]. The number needed to treat (NNT) to achieve an
improvement in sleep quality was 13 but the NNT for
production of an adverse effect was only 6. In addition,
several recent studies have associated the regular use of
sedative drugs with increased mortality [11,12]. Thus,
Spanish guidelines for the management of patients with
anxiety disorders and insomnia in primary care recom-
mend restricting BZD use ton om o r et h a n2 - 4w e e k s
and that long-term users be regularly followed-up
[13-17].
Despite the drawbacks of long-term use of BZDs, such
use remains widespread, with many patients being trea-
ted for several months, years, or even decades. In some
instances, the only reason for continued BZD use is
avoidance of withdrawal symptoms. Although long-term
use is difficult to define, such use is higher in women
than in men and increases with age [2]. For example, a
study in Tarragona (Spain) found that 6.9% of primary
care attendees had taken BZDs for at least 3 months,
including 29% of women older than 65 years [18]. A
French study showed that the prevalence of BZD use in
the general population was 7.5%, including 14.3% of
subjects older than 60 years [19]. Other studies have
estimated the prevalence of long-term BZD use in the
general population at about 2-2.5%[2,20].
Most BZD prescriptions are written by general practi-
tioners (GPs) [21], who often encounter difficulties in
managing withdrawal in patients who become depen-
dent on such agents. The usual clinical protocol for
BZD withdrawal is gradual tapering. Several studies have
tested the effectiveness of different treatment strategies
in decreasing long-term BZD use [22,23]. Gradual taper-
ing approaches may range from minimal interventions
to more complex strategies. In a typical minimal inter-
vention [24-26], a GP may advise patients to discontinue
long-term BZD use without medical assistance by send-
ing a letter that includes information on the negative
consequences of continued use and guidelines on with-
drawal. In contrast, systematic discontinuation programs
are more intensive in nature; patients gradually discon-
tinue BZD dose under the guidance and follow-up care
of a GP [21,27,28]. Addition of either psychological
interventions [27-29] or substitutive pharmacotherapy
[30] to gradual BZD dose reduction has also been evalu-
ated. All these interventions have been found to be
more effective than routine care, but GP involvement
and cost vary considerably [23].
We have designed a study protocol to evaluate the
effectiveness of two interventions, both implemented in
primary care, to withdraw chronic BZD users from such
drugs. The first is an educational intervention reinforced
by a systematic discontinuation program with follow-up
visits, and the second is an educational intervention
reinforced by written support; both will be compared
with routine care. The study is also designed to evaluate
the safety of such interventions, as shown by their
effects on symptoms of anxiety and depression and on
sleep quality and alcohol consumption.
Methods/Design
Design and Settings
The study is designed as a multicenter three-armed
clustered randomized clinical trial in primary care set-
tings in three Spanish Primary Care Health Regions,
with evaluation at 6 months and blind evaluation at 12
months (Figure 1). Long-term BZD users will be
assigned to one of three parallel groups:
a) The first intervention group will receive a struc-
tured interview and follow-up visits (SIF).
b) The second intervention group will receive a
structured interview and written instructions (SIW).
c) A control group (RC) will receive routine care.
Study population
Patients aged 18 to 80 years, who have been taking BZD
or related drugs (zopiclone, zolpidem, or zaleplon) for at
least 6 months and who do not meet any exclusion cri-
terion will be identified from GP clinical records and
invited to participate. Exclusion criteria will include
severe depression or anxiety disorder, a psychotic disor-
der, or a severe personality disorder; current treatment
by a psychiatrist; cognitive impairment or advanced neu-
rological disease; consumption of illegal drugs or alcohol
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exclusion criteria will be presentation with symptoms of
anxiety/depression; a GP view that a subject is likely to
be adversely affected by BZD withdrawal; participation
in any clinical trial within the previous 3 months; and
incapacity or unwillingness to provide written informed
consent.
Recruitment of GPs and patients
Seventy GPs will be contacted through the research
units of each of the three Primary Care Health Districts
and invited to participate. Before random allocation to
one of the three study arms, each GP must recruit eight
patients over a period of 1 month. These patients will
be identified from computerized prescription claims
databases. Pharmaceutical specialties will include the
N05B and N05C groups, and tetrazepam (M03BX07), of
the Anatomical, Therapeutic, and Chemical classification
system of the World Health Organization (WHO). Each
GP will supply a random list of 30 patients; from this
list, 8 eligible patients will be selected after eliminating
patients who meet exclusion criteria and those who
refuse to participate.
Random allocation to study arms
After patients give written informed consent, they will
be included and GPs will be randomized to one of the
three study arms (SIF, SIW or RC group) using a com-
puter-generated block randomization. The randomiza-
tion code will not be revealed until patient recruitment
is complete.
Intervention
All subjects in the SIF and SIW groups will undergo an
educational individualized interview with their GPs. This
standardized interview will cover the following topics:
1) What are BZDs?
2) What happens if an individual takes a BZD for a
long time?
3) Why should I stop taking a BZD?
The concepts of dependence, abstinence, and withdra-
wal syndrome will be discussed, and information on the
importance of gradual dose reduction will be given.
Patients prescribed BZDs for insomnia will be told how
to improve sleep quality. Dose reduction will be dis-
cussed and a tailored dose reduction scheme established.
In general, the scheme will consist of a 10-25% reduc-
tion in daily dose every 2-3 weeks. Patients will be told
about withdrawal symptoms, how to recognize them,
and what to do if they appear.
After the first interview, patients in the SIF group
will be followed up every 2-3w e e k su n t i ld o s er e d u c -
tion is complete. During each visit, information gath-
ered on previous visits will be reviewed, both to
reinforce any positive achievements and to evaluate
adverse effects and/or withdrawal symptoms (e.g., tre-
mor, anxiety, insomnia, convulsions, irritability, and/or
dizziness). Following the first interview, patients in the
SIW group will be given written individualized gradual
dose reduction schedules and will be advised to con-
tact the GP if any problems related to the discontinua-
tion process emerge; the study will not schedule any
subsequent visit.
Patients in both the SIF and SIW groups who con-
tinue to experience withdrawal symptoms will be pre-
scribed a BZD with a longer half-life (diazepam) in
place of any current short half-life BZD that is presently
prescribed.
Patients allocated in control group will receive routine
care for long term users of BZDs.
Training
GPs assigned to the SIF and SIW groups will attend a
workshop 4 hours in duration, to learn how to conduct
the structured interview. The workshop will include
training in methods of managing BZD withdrawal (an
educational standardized interview, provision of indivi-
dualized patient information, and optimal gradual dose
reduction). In addition, GPs assigned to the SIF group
will attend a supplementary 30-minute workshop to
standardize dose reduction follow-up visits. Training
will be provided by collaborative researchers with exten-
sive experience in educating healthcare professionals to
manage cessation of BZD use [13].
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Figure 1 Flow-Chart of participants.
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Measures and variables are summarized, with a time-
line, in Table 1. Self-declared BZD cessation, anxiety,
depression, sleep quality, and alcohol consumption at 6
months will be assessed by the GP. Outcomes at 12
months will be assessed by an external evaluator
blinded to the group to which each patient was
allocated.
All outcome assessors and data analysts will be
blinded to patient group allocation. To evaluate the
effectiveness of blinding, such individuals will be asked
to choose the arm to which they believed each patient
was assigned (possible answers: intervention, usual care,
or unknown). Individuals who respond “intervention” or
“usual care” will be asked to indicate what led to that
belief.
Outcome assessments will include the following:
Primary outcome measure The primary outcome mea-
sure will be BZD cessation at 12 months, defined as
self-reported consumption of fewer than 4 doses per
month, and confirmed using computerized prescription
data over that time period (prescription claims).
Secondary outcome measures The occurrence of symp-
toms of anxiety and depression will be assessed at 0, 6,
and 12 months using the Hospital Anxiety and Depres-
sion (HAD) scale [31,32]. The severity of BZD depen-
dence will be assessed at 0, 6, and 12 months using the
BZD Severity of Dependence (SDS) Scale [33]. Sleep fea-
tures will be assessed at 0, 6, and 12 months using the
Oviedo Sleep Quality Scale [34]. Alcohol consumption
at 0, 6, and 12 months will be self-reported and quanti-
fied by standard drink units.
Adverse Effects
An adverse event will be defined as any unfavorable or
unintended sign, symptom, or disease that could reason-
ably be associated with discontinuation of BZD. These
include tremor, anxiety, insomnia, convulsions, irritabil-
ity, and dizziness. Physicians will report any withdrawal
symptom related to BZD discontinuation to the trial
coordinating center, and the data will analyzed by a
safety committee. Any serious adverse event (e.g. death,
a life-threatening event, inpatient hospitalization or pro-
longation of existing hospitalization, persistent or signifi-
cant disability/incapacity) [35] in any patient in either
intervention group during the course of the study will
be reported to the ethics committee.
Statistical Analysis
Sample size We wish to ensure that the clinical trial has
adequate statistical power to detect a clinically signifi-
cant two-tailed difference of at least 20% and 15% BZD
cessation rates at 1 year in the SIF and SIW groups,
respectively, compared with the usual care group.
Assuming 25% loss to follow-up, we estimate that 129
subjects are needed in each arm.
Table 1 Measures, variables, and timeline
Instrument Assessment area Time(s) of
assessments
Sampling form Inclusion/exclusion criteria Before
randomization
Sociodemographic data form Sociodemographic data: age, gender, educational level, labor status, marital status, number
of persons living in the home, disabled persons under his/her care.
At baseline
Baseline clinical data form Identification of consumed benzodiazepines At baseline
Dosage and duration of benzodiazepines consumed
Original reason for taking benzodiazepines
Comorbid chronic physical or psychological diseases
Benzodiazepine Severity of
Dependence Scale (SDS)
Severity of benzodiazepine dependence At baseline
Hospital Anxiety and Depression
Scale (HADS)
Symptoms of anxiety and depression At baseline, 6 and
12 months
Oviedo Sleep Quality Scale (COS) Sleep quality and features At baseline, 6 and
12 months
Alcohol consumption form Alcohol consumption At baseline, 6 and
12 months
Antidepressant consumption
form
Current consumption of antidepressants At baseline, 6 and
12 months
Current use of benzodiazepine
form
Current consumption of benzodiazepines At baseline, 6 and
12 months
Adverse effects form Adverse effects related to benzodiazepine withdrawal At 6 and 12
months
Use of health resources
questionnaire
Number of primary care visits related to tapering of benzodiazepines At 12 months
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yielding a 1.28 cluster design effect. Thus, the target sample
size for each group is 165 patients, or a total of 495 patients.
Analysis strategy We will test for significant differences
among the baseline characteristics of the control group
and the two intervention groups. We will perform
descriptive analysis, with continuous variables summar-
ized using means and standard deviations for normal
distributions, and by medians and the 25
th and 75
th per-
centiles for non-normal distributions.
All data analyses will involve intention-to-treat popu-
lations (i.e., all randomized patients, regardless of parti-
cipation in any treatment session). This approach
reduces the bias that may occur when participants not
receiving assigned treatments are excluded from analy-
sis. All tests will be two-sided, and a-values of 0.05 will
be considered statistically significant.
We will compare the proportions of patients in each
group discontinuing BZDs at 12 months against the
usual null hypothesis of no difference between propor-
tions. We will use the Chi-squared test, taking into
account the “variance inflation factor” of the physician
cluster and intraclass correlation coefficient. We will
also calculate 95% confidence intervals to assess the
clinical significance of interventions.
In multivariate analysis, we will adjust for potential
confounders, if any, using a logistic regression model.
We will estimate relative and absolute risk reduction
and the number needed to treat, defined as the esti-
mated number of patients who need to be treated with
the intervention (rather than routine care) for one addi-
tional patient to be controlled.
We will determine the safety of interventions by com-
paring levels of anxiety, depression, and sleep quality at
12 months among the three groups, using the Chi-
s q u a r e dt e s ta n dS t u d e n t ’s t-test, corrected by VIF and
intraclass correlation coefficient. The proportion of
patients with serious adverse events related to BZD dis-
continuation will also be compared.
All estimates will include 95% confidence intervals.
The number needed to treat will be calculated as the
reciprocal of the difference between the proportion of
patients controlled in each intervention group and the
control group.
Ethical approval
Our study protocol has been approved by the Primary
Care Research Committee and the Mallorca Ethical
Committee of Clinical Research (IB 1146/09 PI).
Limitations
Physicians assigned to the control group may be aware
that some interventions can be effective in terms of
BZD withdrawal. Thus, the decision by a GP to partici-
pate in this study may be associated with a greater
motivation to facilitate BZD withdrawal. GPs allocated
to usual care may therefore be more liable to discon-
tinue patients from long-term BZD use than will be
other GPs. Thus, even patients receiving usual care may
be influenced by participation in a clinical trial (the
Hawthorne effect).
Clinical trials, in which patients are randomized to an
interventional or control group, with the same GP
assisting both groups, usually suffer from contamination
bias. We have therefore designed a clustered rando-
mized trial, to avoid contamination at the GP level.
However, if GPs allocated to different study arms are
working in the same Healthcare Centre, a contamination
bias may arise if control GPs learn about and deliver the
intervention. Were this to occur, the expected differ-
ences between groups would decrease.
In clustered clinical trials, in which patient inclusion
occurs after randomization, the refusal of a significant
number of interventional patients to participate may intro-
duce a selection bias. All patients in our study will be
included before randomization to avoid such bias, and
baseline characteristics will be compared to guarantee that
important factors are balanced across treatment groups.
Discussion
Patients, especially the elderly, would clearly benefit from
BZD withdrawal, in that the risks of falls and cognitive
impairment would drop, as would the excess mortality
rates observed in patients taking anxiolytic drugs [11,12].
Several studies have assessed the effectiveness of strate-
gies used to discontinue patients from long-term BZD
use. However, the various interventions differed in meth-
odology, overall effectiveness, and cost-effectiveness. For
example, interventions involving the sending of letters to
long-term BZD users had adequate sample sizes and
were cost-effective, but only o n ei nf i v ep a t i e n t sc e a s e d
BZD use. Gradual discontinuation interventions are
much more effective, with variable cessation rates, but
such trials have usually had small sample sizes. Provision
of psychological support was somewhat more effective
than was gradual tapering alone, but professional time
requirements and costs were much higher [22,23].
A maximally effective withdrawal strategy, at minimal
cost and with a low need for professional time, is espe-
cially important in primary care settings because of bud-
getary limitations and the small amount of GP time
available per consultation. We expect that the combina-
tion of an educational intervention (reinforced by written
information) and an individually tailored tapering pro-
gram will achieve a discontinuation rate not much lower
than that of a systematic discontinuation program with
follow-up visits, and will consume less professional time.
Despite the increase in research on interventions
effective to cause BZD use cessation, it may be difficult
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lenge that our objective poses to GPs. This study has
therefore been designed to compare whether such inter-
ventions are effective and safe compared with routine
care.
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